

FOI REF: 22/267

31st May 2022

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

[These responses below are for the months February – April 2022 inclusive.](#)

• Adalimumab – Humira	<5
• Adalimumab Biosimilar	22
• Apremilast	<5
• Bimekizumab	0
• Brodalumab	<5
• Certolizumab	<5
• Dimethyl fumarate	<5
• Etanercept – Enbrel	0
• Etanercept Biosimilar	<5
• Guselkumab	7
• Infliximab – Remicade	0
• Infliximab Biosimilar	<5
• Ixekizumab	<5
• Risankizumab	0
• Secukinumab	9
• Tildrakizumab	0
• Ustekinumab	86

Cont.../

Q2. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

• Adalimumab – Humira	30
• Adalimumab Biosimilar	198
• Filgotinib	0
• Golimumab	<5
• Infliximab – Remicade	6
• Infliximab Biosimilar	78
• Ozanimod	0
• Tofacitinib	5
• Ustekinumab	92
• Vedolizumab	99

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net